Trillium Therapeutics Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Research and development
General and administrative
Impairment of intangible assets
Operating expenses
Loss from operating activities
Finance income
Finance costs
Net foreign currency loss (gain)
Revaluation of warrant liability, net
Net finance costs (income)
Loss before income taxes
Current income tax expense
Net loss for the year
Impact of change in presentation currency
Net loss and comprehensive loss for the year
Basic and diluted loss per common share
REVENUE
OPERATING EXPENSES
Research and development
General and administrative
Total operating expenses
Operating loss
Other income (expense)
Interest income, net
Net foreign currency gain (loss)
Revaluation of warrant liability
Total other income (expense), net
Net loss before income taxes
Income tax expense
Net loss
Other comprehensive income
Foreign currency translation adjustments
Total other comprehensive income
Comprehensive loss
Net loss per share, basic and diluted
Weighted average number of common shares used in computing net loss per share, basic and diluted

Comments